Compare RAVE & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAVE | IXHL |
|---|---|---|
| Founded | 1958 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 45.0M |
| IPO Year | 1995 | 2024 |
| Metric | RAVE | IXHL |
|---|---|---|
| Price | $2.44 | $3.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.1K | ★ 468.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $15,120,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $0.11 |
| 52 Week High | $3.75 | $6.39 |
| Indicator | RAVE | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 55.82 |
| Support Level | $2.28 | $0.34 |
| Resistance Level | $3.49 | $3.68 |
| Average True Range (ATR) | 0.18 | 0.33 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 16.00 | 60.50 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.